Abstract: Formulations and methods of treatment for a patient infected with Sudan vims are provided. The formulation comprises a therapeutically effective combination of: (i). a first monoclonal antibody comprising a heavy chain variable region comprising an amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ. ID NO: 5, and a light chain variable region comprising an amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID NO: 6, therapeutically effective mutations, and humanized variants thereof, and humanized variants thereof; (ii). a second monoclonal antibody comprising a heavy chain variable region comprising an amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ. ID NO: 13 and a light chain variable region comprising an amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID NO: 14, therapeutically effective mutations, and humanized variants thereof.

Abstract: Provided here are immunoglobulins and compositions containing one or more of said immunoglobulins reactive to a strain of Marburg virus. The immunoglobulins and compositions comprising said immunoglobulins can be used prophylactically to prevent a Marburg virus infection or to treat a patient that has been exposed to a Marburg virus in order to reduce a symptom.

Abstract: Provided here are immunoglobulins and compositions containing one or more of said immunoglobulins reactive to a strain of Marburg virus. The immunoglobulins and compositions comprising said immunoglobulins can be used prophylactically to prevent a Marburg virus infection or to treat a patient that has been exposed to a Marburg virus in order to reduce a symptom.

Abstract: An immunoglobulin of the G class (IgG) directed against the protective antigen (PA) of the anthrax toxin, includes: a light-chain variable region including an amino-acid sequence having at least 90% amino-acid identity with the sequence SEQ ID No1 such as defined in the description, and a heavy-chain variable region including an amino-acid sequence having at least 90% amino-acid identity with the sequence SEQ ID No2 such as defined in the description, characterized in that it consists of an IgG1 or an IgG2.

Abstract: A chimeric monoclonal antibody targeted to ricin is presented. The light chain and heavy chain constant regions are respectively made up of the light chain and heavy chain constant regions of human immunoglobulin, and the light chain and heavy chain variable regions respectively include the light chain and heavy chain variable regions of macaque immunoglobulin. The antibody does not substantially induce any immune response against chimeric antibodies.

Abstract: A chimeric monoclonal antibody targeted at ricin, in which the light chain and heavy chain are such that: the constant region of the light chain and the constant region of the heavy chain are essentially made up respectively of the constant region of the light chain and the constant region of the heavy chain of human immunoglobulin, the variable region of the light chain and the variable region of the heavy chain include respectively the variable region of the light chain and the variable region of the heavy chain of macaque immunoglobulin, the monoclonal antibody not substantially inducing an immune response against chimeric antibodies.

Abstract: A method of preparing a germinalized hypervariable antibody region directed against a target, as well as the antibodies, antibody fragments, vectors and compositions including the germinalized hypervariable region.

Abstract: The subject of the present invention is an anti-ricin antibody and the use thereof for the treatment of an individual suffering from ricin poisoning.

Abstract: A chimeric monoclonal antibody targeted at ricin, in which the light chain and heavy chain are such that: the constant region of the light chain and the constant region of the heavy chain are essentially made up respectively of the constant region of the light chain and the constant region of the heavy chain of human immunoglobulin, the variable region of the light chain and the variable region of the heavy chain include respectively the variable region of the light chain and the variable region of the heavy chain of macaque immunoglobulin, the monoclonal antibody not substantially inducing an immune response against chimeric antibodies.

Abstract: An immunoglobulin of the G class (IgG) directed against the protective antigen (PA) of the anthrax toxin, includes: a light-chain variable region including an amino-acid sequence having at least 90% amino-acid identity with the sequence SEQ ID No 1 such as defined in the description, and a heavy-chain variable region including an amino-acid sequence having at least 90% amino-acid identity with the sequence SEQ ID No 2 such as defined in the description, characterized in that it consists of an IgG1 or an IgG2.

Abstract: The subject of the present invention is an anti-ricin antibody and the use thereof for the treatment of an individual suffering from ricin poisoning.

Abstract: The invention relates to an anti PA antibody, in which the variable region of the heavy chain has an amino acid sequence represented by SEQ ID N°1 and in which the variable sequence of the light chain has an amino acid sequence represented by SEQ ID N°2, that is modified in order to improve its affinity and its tolerance in human beings.